-
Do tea and coffee have an effect on the occurrence of gliomas?
Time of Update: 2020-12-19
Study The study assessed the correlation between tea, coffee and caffeine intake and the development of gliomas in the Women's Nurses' Health Study (NHS), Nurses' Health Research Phase II., and The Male Health Professional Follow-up Study (HPFS).
-
Nat Commun: Scientists hope to use artificial intelligence to predict a combination of drugs that can effectively kill cancer cells
Time of Update: 2020-12-19
December 5, 2020 // -- In a recent study published in the international journal Nature Communications, scientists from the University of Alto and others said that artificial intelligence technology could be used to predict which combinations of drugs could effectively kill cancer cells.
-
New risk factors for meningoma haemorrhage
Time of Update: 2020-12-19
study method 1 case of 56-year-old female patients, post-menoptosis to receive high-dose estrogen replacement therapy, accompanied by a stable chest aortic aneurysm history and history of depression, taking citopram 20 mg/day.
-
Cell Rep: Scientists have successfully revealed the origins and new molecular mechanisms of cancer cell metastasis
Time of Update: 2020-12-19
Linking transcriptional groups to the metastasis esotypes of single cells in colon cancer tumors, they identified the importance of a gene called VSIG1 in cell-to-cell interactions, which can effectively inhibit cancer metastasis, and studies that may hopefully help scientists develop new treatments for cancer, while researchers have also confirmed that the new technology can detect drugs that fight cancer metastasis, including some individualized anti-cancer drugs.
-
CD19 CAR-T Cell Therapy! Novarma Kymriah Treatment of Recurrence or Refractic Foly Lymphoma (FL): Total remission rate 83%!
Time of Update: 2020-12-19
as we go deeper into CAR-T cell therapy, these new analyses demonstrate Kymriah's potential to rewrite cancer survival rates in some patients with advanced lymphoma.
" Photo Source: childrenshospital.org-ELARA Study Interim Analysis: 52 patients with assessable efficacy, median follow-up time of 9.9 months, Kymriah for most of the patients treated.
-
Postoperative follow-up of diffuse low-grade gliomas with WHO III./IV. lesions
Time of Update: 2020-12-18
Amelie Darlix of the Oncology Department at montpellier University Hospital in France and other retrospective analyses of the functional recovery and survival of DLGG patients with malignant tumor components who delayed complementary therapy after surgery were published online in January 2020.
-
BCMA CAR-T Therapy! Baishi Meishi Guibaoide-cel treatment of multiple myeloma: deep lasting relief, improve the quality of life!
Time of Update: 2020-12-18
-KarMMa Study Analysis: Subgroup analysis of outcomes in high-risk and elderly RRMM patients and health-related quality of life analysis showed that ide-cel showed deep and lasting remission in RRMM patients who had been on class 3 drugs.
-
CD19 CAR-T Cell Therapy! Gilead Yescarta's first-line treatment of high-risk large cell lymphoma (LBCL) has a complete remission rate of up to 74%!
Time of Update: 2020-12-18
"Yescarta, approved by the FDA in October 2017, is the first CAR-T cell therapy to treat adult patients with relapsed or refractic large B-cell lymphoma (LBLC) Treatment in adult patients with therapeutic LBCL includes diffuse large B-cell lymphoma (DLBCL), primary vertical large B-cell lymphoma (PMBCL), high-level B-cell lymphoma (HGBL), and DLBCL (i.e., transformed FL, TFL) derived from fable lymphoma (FL).
-
CD19 CAR-T Cell Therapy! Gilead Yescarta Treatment Recurrence/Difficult Inert Non-Hodgkin's Lymphoma (iNHL): Total remission rate of 92%!
Time of Update: 2020-12-18
data released at the ASH Annual Meeting showed that after receiving Yescarta's single infusion treatment, the medium follow-up was 17.5 months: 92% of the 104 patients with assessable efficacy were in remission (ORR-92%) and 76% were fully relieved (CR-76%).
-
Beval beads inhibit brain metastasis in lung cancer
Time of Update: 2020-12-18
methods The authors used simulated clinical blood-brain barrier models to study the effects of beva bead monomorphic osmosis to brain metastasis lesions and anti-tumor microvascular production.
-
Br J Cancer: RON promotes therapeutic resistance to ESR1 mutant breast cancer
Time of Update: 2020-12-17
inhibitor RON signaling path can restore ET sensitivity, the results show that inhibition of RON/PI3K paths may be a potentially effective treatment strategy for patients with ESR1 mutants and PalbR MBC.
-
Br J Cancer: TriCurin, a new phytochemical mixture, inhibits the growth of cervical cancer cells
Time of Update: 2020-12-17
previous studies have shown that the phytochemical mixture TriCurin (curcubin, EGCG and resveratrol) eliminates HPV-positive cancer cells.
TriCurin and its monosomes inhibited the growth of precanceral lesions W12 cells using experimental techniques such as MTT and RT-PCR to determine the activity of TriCurin and its monosome compounds in W12 cells derived from cervical cancer derived from free and integrated HPV16 DNA.
-
Br J Cancer: Tumor acidosis is associated with the metastasis potential of breast cancer
Time of Update: 2020-12-17
the migration and invasiveness of TUBO, 4T1, and TS/A cells analyzed the metastasis potential of several breast cancer cell linees using aggressive and invasive tumor markers.
, the researchers observed a significant correlation between higher tumor acidity and an increase in lung metastasis.
-
Cancer: The effects of ± treatment of distant metastasis with the treatment of phosphons
Time of Update: 2020-12-17
study aims to compare differences in survival rates after distant recurrence in patients receiving different complementary endocrine treatments in the BIG 1-98 trial.
-
The new LAIR1 antagonist NCM438 may be used to treat advanced solid tumors
Time of Update: 2020-12-17
lair1 and collagen are raised in a variety of cancer types, where collagen is produced by active substring cells.
NCM438 is designed to inhibit the interaction between LAIR1 and the substring-derived collagen and has the potential to block the substation checkpoint and restore the anti-tumor immune response.
-
Radiology: How much breast cancer will be missed without digital mammography?
Time of Update: 2020-12-16
as a whole, breast cancers examined with DBT were mostly immersive (P .lt; .001), had fewer positive lymph nodes (P .04) and distant metastasis (P s .01), and had a lower rate of FN incidence of advanced breast cancer (odds ratio, 0.95% CI: 0.5, 1.5).
-
Nat Commun: Clinical deep learning models can be used for the detection of intracranial aneurysms in angioenic images
Time of Update: 2020-12-16
and timely and accurate identification of IAs is essential for immediate intervention or surgical treatment in SAH patients.
the model's impact on clinical practice in suspected IAs patients in emergency departments has shown that it has good tolerance for image quality and has been tested in different manufacturers.
-
Br J Cancer: TNIK inhibitor NCB-0846 blocks the TGF beta/SMAD signaling path path to inhibit the metastasis of lung cancer
Time of Update: 2020-12-16
study explores the effects of NCB-0846 on the EMT process of lung cancer induced by TGF beta1.
NCB-0846 inhibits the metastasis of lung cancer cells Researchers have found that NCB-0846 inhibits the EMT process of TGF beta-induced A549 cells.
-
Cell Death Dis: SKIL promotes the occurrence and immune escape of non-small cell lung cancer
Time of Update: 2020-12-16
and silence TAZ eliminated the effects of expressive SKIL on the malignancy of NSCLC cells and autophagy.
in general, SKIL promotes tumor occurrence and immune escape of NSCLC by raising the expression of TAZ and promoting cell autophagy and inhibiting downstream STING signaling pathps.
-
Eur J Cancer: Results of Phase 3 clinical trials of critical prostate cancer in the combined radiotherapy of androgen deprivation therapy
Time of Update: 2020-12-16
, in patients with IRPC, the addition of six months of ADT on top of RT70 or DERT76 significantly improves BF compared to SINGLE DERT76, while also reducing the risk of prostate cancer death without affecting total survival.
, patients with critical prostate cancer in the ADT joint RT 70GY treatment had effective disease control and lower gastrointestinal toxicity.
